Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Single-Cell Multiomics Unveils Venetoclax-Resistant Monocytic Differentiation and Immune Evasion in TP53 Mutant AML Clones

Edward Ayoub, David Lehotzky, Li Li, Muharrem Muftuoglu, Yuki Nishida, Vakul Mohanty, Jake S Leighton, Tallie Patsilevas, Mahesh Basyal, Andrea Bedoy, Torsten Haferlach, Koichi Takahashi, Ken Chen, Nicholas Navin, Ghayas C. Issa, Gad Getz, Michael Andreeff

Blood (2024) 144 (Supplement 1): 61.

https://doi.org/10.1182/blood-2024-211845

Published: 2024

Journal Articles

Spatial Analysis of Human p53 Mutated AML Bone Marrow Reveals Novel MRD Clusters and Spatial Microenvironmental Features of p53 Mutated AML

Hideaki Mizuno, Yuki Nishida, Edward Ayoub, Akshay Basi, Andrea Bedoy, Javier A. Gomez, Jared K. Burks, Rashmi Kanagal-Shamanna, Michael Andreeff

Blood (2024) 144 (Supplement 1): 1301.

https://doi.org/10.1182/blood-2024-209852

Published: 2024

Journal Articles

Targeting Co-Regulatory Feedback Loop of MYC and GSPT1 By MYC/GSPT1 Dual Degradation Is Synthetic Lethal in Combination with Ven/Aza in TP53 Mutant Acute Myeloid Leukemia Stem and Progenitor Cells

Yuki Nishida, Hideaki Mizuno, Edward Ayoub, Eiji Sugihara, Lauren B. Ostermann, Shayaun Khazaei, Darah Scruggs, Po Yee Mak, Baozhen Ke, Bing Z. Carter, Abhishek Maiti, Liandong Ma, Michael Andreeff

Blood (2024) 144 (Supplement 1): 2755.

https://doi.org/10.1182/blood-2024-207812

Published: 2024

Journal Articles

Selective Targeting of TP53-Y220C Mutant AML By PC14586 Results in TP53 Wild-Type Conformation and Synergistical Apoptosis Induction By Concomitant Inhibition of Xpo-1, MDM2, or Bcl-2

Bing Z. Carter, Po Yee Mak, Baozhen Ke, Yuki Nishida, Steffen Boettcher, Andrea Bedoy, Lauren B. Ostermann, Courtney D. DiNardo, Anna Puzio-Kuter, Arnold Levine, Michael Andreeff

Blood (2023) 142 (Supplement 1): 2261.

https://doi.org/10.1182/blood-2023-181186

Published: 2023

Journal Articles

Targeted Protein Degradation for c-MYC Overcomes Therapy Resistance in T-Cell Acute Lymphoblastic Leukemias

Faryal Munir, Shayaun Khazaei, Phoebe H. Calkins, Darah Scruggs, Hideaki Mizuno, Lauren B. Ostermann, Branko Cuglievan, Miriam B. Garcia, Dong Chen, Youzhi Tong, Zhihua Ren, Michael Andreeff, Yuki Nishida

Blood (2023) 142 (Supplement 1): 1447.

https://doi.org/10.1182/blood-2023-187496

Published: 2023

Journal Articles

Stem-Cell Enriched Cellular Hierarchy of TP53 Mutant Acute Myeloid Leukemia Is Vulnerable to Targeted Protein Degradation of c-MYC

Blood (2023) 142 (Supplement 1): 583.

https://doi.org/10.1182/blood-2023-174938

Published: 2023

Journal Articles

Single-Cell Genomics and Proteomics Reveals Venetoclax-Resistant Monocytic Differentiation of TP53 LOH Clones in TP53 Mutant AML

Edward Ayoub, Li Li, Muharrem Muftuoglu, Yuki Nishida, Vakul Mohanty, Jake S Leighton, Tallie Patsilevas, Mahesh Basyal, Andrea Bedoy, Torsten Haferlach, Koichi Takahashi, Ken Chen, Nicholas Navin, Ghayas C. Issa, Michael Andreeff

Blood (2023) 142 (Supplement 1): 5014.

https://doi.org/10.1182/blood-2023-187121

Published: 2023

Journal Articles

Epichaperome inhibition targets TP53- mutant AML and AML stem/progenitor cells

Blood (2023) 142 (12): 1056–1070.

https://doi.org/10.1182/blood.2022019047

Published: 2023

Includes: Supplemental data

Journal Articles

C-MYC Targeting By Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Induces TP53 -Independent Cell Death in Acute Myeloid Leukemia and Lymphomas

Yuki Nishida, Darah A Scruggs, Edward Ayoub, Tallie Patsilevas, Vivian Ruvolo, Po Yee Mak, Bing Z Carter, Steffen Boettcher, Abhishek Maiti, Qianxiang Zhou, Zhaohui Yang, Honghua Yan, Liandong Ma, Michael Andreeff

Blood (2022) 140 (Supplement 1): 483–484.

https://doi.org/10.1182/blood-2022-164968

Published: 2022

Journal Articles

Epichaperome Inhibition Targets Kinase and TP53 Mutant Therapy Resistant AML

Bing Z Carter, Po Yee Mak, Wenjing Tao, Lauren B Ostermann, Yuki Nishida, Naveen Pemmaraju, Steffen Boettcher, Elizabeth J Shpall, Gabriela Chiosis, Georgios Karras, Barbara Wallner, Robert A Morgan, Michael Andreeff

Blood (2022) 140 (Supplement 1): 5930–5931.

https://doi.org/10.1182/blood-2022-158547

Published: 2022

Journal Articles

Polyploidy Is Necessary for Apoptotic Cell Death in TP53 -Mut AML in Response to Polo-like-Kinase 4 (PLK4) Inhibition and Results in Caspase 3 Cleavage

Edward Ayoub, Akhil Marupudi, Yuki Nishida, Rafael Heinz Montoya, Vakul Mohanty, Wencke Walter, Mark R Bray, Tallie Patsilevas, Steffen Boettcher, Ghayas C. Issa, Ken Chen, Torsten Haferlach, Gautam Borthakur, Michael Andreeff

Blood (2022) 140 (Supplement 1): 5941–5943.

https://doi.org/10.1182/blood-2022-170152

Published: 2022

Journal Articles

Mitochondrial Regulation of Ferroptosis in Acute Myeloid Leukemia

Hiroki Akiyama, Ran Zhao, Yuki Nishida, Natalia Baran, Ziyi Li, Lauren B Ostermann, Po Yee Mak, Edward Ayoub, Sujan Piya, Bing Z Carter, Michael Andreeff, Jo Ishizawa

Blood (2022) 140 (Supplement 1): 8785–8786.

https://doi.org/10.1182/blood-2022-162354

Published: 2022

Journal Articles

Therapeutic Targeting of Ferroptosis Pathway in Combination with Mitochondrial Oxidative Stress Induction in Acute Myeloid Leukemia

Hiroki Akiyama, Ran Zhao, Adam Rahhal, Yuki Nishida, Edward Ayoub, Lauren B Ostermann, Michael Andreeff, Jo Ishizawa

Blood (2021) 138 (Supplement 1): 1162.

https://doi.org/10.1182/blood-2021-148248

Published: 2021

Journal Articles

Enhanced p53 Activation By Dual Inhibition of MDM2 and XPO1 Disrupts MYC Transcriptional Program and Restores Sensitivity to BCL-2 Inhibition in Ven/HMA Resistant AML

Yuki Nishida, Jo Ishizawa, Edward Ayoub, Tallie Patsilevas, Lauren Ostermann, Rafael Heinz Montoya, Muharrem Muftuoglu, Vivian Ruvolo, Po Yee Mak, Wenjing Tao, Bing Z Carter, Kensuke Kojima, Naval Daver, Arnaud Lesegretain, Takahiko Seki, Sharon Shacham, Marina Konopleva, Michael Andreeff

Blood (2021) 138 (Supplement 1): 505.

https://doi.org/10.1182/blood-2021-149260

Published: 2021

Journal Articles

Combined Blockade of CD47-Sirpa Interaction By 5F9 (Magrolimab) and Azacitidine/Venetoclax Therapy Facilitates Macrophage-Mediated Anti-Leukemia Efficacy in AML Pre-Clinical Models

Yannan Jia, Qi Zhang, Connie Weng, Cassandra L Ramage, Yuki Nishida, Mark Chao, Roy Louis Maute, Shelley Herbrich, Weiguo Zhang, Michael Andreeff, Naval Daver, Marina Konopleva

Blood (2021) 138 (Supplement 1): 510.

https://doi.org/10.1182/blood-2021-147479

Published: 2021

Journal Articles

Combined Inhibition of Bcl-2 and Mcl-1 Circumvents Resistance of TP53 Deficient/Mutant AML to BH3 Mimetics

Bing Z Carter, Po Yee Mak, Wenjing Tao, Lauren B Ostermann, Steffen Boettcher, Yuki Nishida, Edward Ayoub, Vivian Ruvolo, Elias J. Jabbour, Paul Hughes, PK Morrow, Michael Andreeff

Blood (2021) 138 (Supplement 1): 2239.

https://doi.org/10.1182/blood-2021-148014

Published: 2021

Journal Articles

Co-Targeting Intrinsic and Extrinsic Apoptosis to Maximize Cell Death Induction in Venetoclax-Resistant AML Cells

Bing Z Carter, Wenjing Tao, Lauren B Ostermann, Hong Mu-Mosley, Po Yee Mak, Steffen Boettcher, Yuki Nishida, Ran Tao, Eric Lang, Yifan Zhai, Dajun Yang, Michael Andreeff

Blood (2021) 138 (Supplement 1): 3332.

https://doi.org/10.1182/blood-2021-148127

Published: 2021

Journal Articles

Co-Targeting MCL-1 and BCL-2 Is Highly Synergistic in BH3 Mimetic- and Venetoclax/Hypomethylating Agent-Resistant and TP53 Mutated AML

Bing Z Carter, PhD, Po Yee Mak, Wenjing Tao, Vivian Ruvolo, MS, Xuan Zhang, PhD, Yuki Nishida, MD PhD, Steven M. Kornblau, MD, Paul Hughes, Xiaoyue Chen, PK Morrow, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 7.

https://doi.org/10.1182/blood-2020-141417

Published: 2020

Journal Articles

Clonal Expansion of Mutant p53 Clones By MDM2 Inhibition in Acute Myeloid Leukemias

Yuki Nishida, MDPhD, Rafael Heinz Montoya, BS, Kiyomi Morita, MDPhD, Tomoyuki Tanaka, MDPhD, Feng Wang, PhD, Koichi Takahashi, MD PhD, Jo Ishizawa, MDPhD, Prasanna Kumar, PhD, Parul Patel, PhD, Cedric E. Dos Santos, PhD, Courtney D. DiNardo, MD MSCE, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-142794

Published: 2020

Journal Articles

Inhibition of EZH1 and EZH2 Restores Chemosensitivity of Leukemia Stem Cells in Acute Myeloid Leukemia By Recruitment of Quiescent AML Stem/Progenitor Cells

Kyung Hee Chang, PhD, Zoe Alaniz, Yuki Nishida, MDPhD, Cedric E. Dos Santos, PhD, Eric Slosberg, PhD, Naval Daver, MD, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-142071

Published: 2020

NARROW

Single-Cell Multiomics Unveils Venetoclax-Resistant Monocytic Differentiation and Immune Evasion in TP53 Mutant AML Clones

Spatial Analysis of Human p53 Mutated AML Bone Marrow Reveals Novel MRD Clusters and Spatial Microenvironmental Features of p53 Mutated AML

Targeting Co-Regulatory Feedback Loop of MYC and GSPT1 By MYC/GSPT1 Dual Degradation Is Synthetic Lethal in Combination with Ven/Aza in TP53 Mutant Acute Myeloid Leukemia Stem and Progenitor Cells

Selective Targeting of TP53-Y220C Mutant AML By PC14586 Results in TP53 Wild-Type Conformation and Synergistical Apoptosis Induction By Concomitant Inhibition of Xpo-1, MDM2, or Bcl-2

Targeted Protein Degradation for c-MYC Overcomes Therapy Resistance in T-Cell Acute Lymphoblastic Leukemias

Stem-Cell Enriched Cellular Hierarchy of TP53 Mutant Acute Myeloid Leukemia Is Vulnerable to Targeted Protein Degradation of c-MYC

Single-Cell Genomics and Proteomics Reveals Venetoclax-Resistant Monocytic Differentiation of TP53 LOH Clones in TP53 Mutant AML

Epichaperome inhibition targets TP53- mutant AML and AML stem/progenitor cells

C-MYC Targeting By Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Induces TP53 -Independent Cell Death in Acute Myeloid Leukemia and Lymphomas

Epichaperome Inhibition Targets Kinase and TP53 Mutant Therapy Resistant AML

Polyploidy Is Necessary for Apoptotic Cell Death in TP53 -Mut AML in Response to Polo-like-Kinase 4 (PLK4) Inhibition and Results in Caspase 3 Cleavage

Mitochondrial Regulation of Ferroptosis in Acute Myeloid Leukemia

Therapeutic Targeting of Ferroptosis Pathway in Combination with Mitochondrial Oxidative Stress Induction in Acute Myeloid Leukemia

Enhanced p53 Activation By Dual Inhibition of MDM2 and XPO1 Disrupts MYC Transcriptional Program and Restores Sensitivity to BCL-2 Inhibition in Ven/HMA Resistant AML

Combined Blockade of CD47-Sirpa Interaction By 5F9 (Magrolimab) and Azacitidine/Venetoclax Therapy Facilitates Macrophage-Mediated Anti-Leukemia Efficacy in AML Pre-Clinical Models

Combined Inhibition of Bcl-2 and Mcl-1 Circumvents Resistance of TP53 Deficient/Mutant AML to BH3 Mimetics

Co-Targeting Intrinsic and Extrinsic Apoptosis to Maximize Cell Death Induction in Venetoclax-Resistant AML Cells

Co-Targeting MCL-1 and BCL-2 Is Highly Synergistic in BH3 Mimetic- and Venetoclax/Hypomethylating Agent-Resistant and TP53 Mutated AML

Clonal Expansion of Mutant p53 Clones By MDM2 Inhibition in Acute Myeloid Leukemias

Inhibition of EZH1 and EZH2 Restores Chemosensitivity of Leukemia Stem Cells in Acute Myeloid Leukemia By Recruitment of Quiescent AML Stem/Progenitor Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only